SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
March 20 2008 - 6:00AM
PR Newswire (US)
SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals,
Inc. (NASDAQ:SGXP) will be presenting at the Future Leaders in the
Biotech Industry Conference hosted by BioCentury and Thomson on
Thursday, March 27, 2008 at 9:00 AM Eastern Daylight Time. Mike
Grey, president and chief executive officer of SGX Pharmaceuticals,
will provide an overview of the Company's oncology pipeline. The
conference is being held at the Millennium Broadway Hotel and
Conference Center in New York City. A live webcast of the
presentation will be available under the investor relations section
of the Company's website at http://www.sgxpharma.com/. Replays of
the presentation will be available for 90 days following the event.
Please connect to the Company's website several minutes prior to
the start of the broadcast to ensure adequate time for any software
download that may be necessary. About SGX Pharmaceuticals SGX
Pharmaceuticals is a biotechnology company focused on the
discovery, development and commercialization of innovative cancer
therapeutics. The SGX oncology pipeline includes drug candidates
from its FAST(TM) drug discovery platform, such as SGX523, a MET
kinase inhibitor currently in Phase 1 clinical studies, next
generation BCR-ABL inhibitors being developed by SGX and in
partnership with Novartis and a portfolio of inhibitors of various
oncology targets. More information on the pipeline and drug
discovery platform can be found at http://www.sgxpharma.com/ and in
the Company's various filings with the Securities and Exchange
Commission. DATASOURCE: SGX Pharmaceuticals, Inc. CONTACT: Bonnie
Feldman, Sr. Director, Investor Relations, of SGX Pharmaceuticals,
Inc., +1-858-344-8860 Web site: http://www.sgxpharma.com/
Copyright
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
Historical Stock Chart
From Aug 2023 to Aug 2024